Device Trial Radar · NCT07859358
Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jan 20, 2026
Primary completion
Apr 20, 2026
Study completion Jul 10, 2026
Sponsor
- Lead sponsor
- Assiut UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Periodontitis is a chronic multifactorial inflammatory disorder affecting the periodontium, often implicated with microbial dysbiosis. Following the establishment of a proper diagnosis, the initial therapeutic phase within the recommended protocol must focus patient motivation and behavior alongside the comprehensive management of modifiable local and systemic risk factors. Although SRP effectively reduces microbial load, complete regeneration of periodontal tissues remains challenging due to limited healing potential and persistent inflammation. Various adjunctive therapies have been explored to enhance periodontal healing, including oxygen-based and platelet concentrate approaches. Topical oxygen therapy has recently gained attention for its antimicrobial and regenerative properties. Oxygen-releasing gels, such as those containing stabilized hydrogen peroxide, increase local oxygen tension, inhibit anaerobic pathogens, and promote angiogenesis and fibroblast proliferation, resulting in improved clinical parameters following SRP. Injectable platelet-rich fibrin (i-PRF), a second-generation autologous platelet concentrate, provides a sustained release of growth factors such as PDGF, VEGF, and TGF-β, enhancing soft tissue healing and bone regeneration. Clinical trials have demonstrated that i-PRF used with SRP significantly improves probing depth reduction, attachment gain, and bleeding scores compared with SRP alone. However, no studies have directly compared oxygen therapy and i-PRF as adjuncts to non-surgical periodontal therapy. Investigating these two bio stimulatory approaches could identify a minimally invasive, cost-effective strategy to optimize periodontal healing and regeneration.
Conditions
- Stage III Periodontitis
Interventions
Injectable Platelet-Rich Fibrin (i-PRFBiological
Autologous injectable platelet-rich fibrin prepared chairside from 10 mL patient venous blood collected in plain plastic tubes without anticoagulant. Blood centrifuged at 700 rpm (60g) for 3 minutes using fixed-angle centrifuge at room temperature. Supernatant liquid fraction (upper 4-5 mL, yellowish) collected via 3 mL syringe with 27G needle. Immediately injected subgingivally (1-2 mL per site) through custom acrylic stent notches targeting sites with CAL ≥4 mm and PPD ≥5 mm. Applied at baseline + weeks 2, 4, 6, 8 (5 total applications). Contains PDGF-BB, TGF-β1, VEGF, IGF-1, and viable leukocytes for sustained regenerative effect over 7-10 days.
Peroxoborate Oxygen-Releasing Oral GelDrug
Stabilized peroxoborate/peroxide-based oxygen-releasing dental gel (5-10% active oxygen equivalent, neutral pH 6.8-7.2). Applied via 3 mL blunt-tip syringe (27G) through acrylic stent notches (1-2 mL per site) to fill CAL ≥4 mm, PPD ≥5 mm periodontal pockets completely. Provides continuous oxygen release (O2 + reactive oxygen species) for 24-48 hours, creating anaerobic microenvironment disruption, bacterial kill, and enhanced tissue oxygenation. Applied at baseline + weeks 2, 4, 6, 8 (5 total applications). Excess gel expressed from pocket orifice confirms complete filling
Scaling and Root Planing (SRP)Procedure
Full-mouth non-surgical periodontal debridement performed in 2 sessions (45-60 min each, 1-week interval). Supragingival/subgingival scaling using ultrasonic scaler (Cavitron, 30K Hz) + hand instruments (Gracey curettes 11/12, 13/14, universal 7/8). Root planning to remove cementum-embedded calculus and bacterial toxins from root surfaces. Sites with PPD ≥5 mm receive special attention. Local anesthesia (2% lidocaine 1:100K epi) as needed. Post-SRP oral hygiene instructions: modified Bass brushing technique (2x daily), interdental brushes/floss
Custom Acrylic Probing StenDevice
Individually fabricated acrylic stent (2-3 mm thick) from alginate impression of maxillary/mandibular study teeth. Vertical grooves/notches (2 mm deep) cut at mesio-buccal, mid-buccal, disto-buccal sites using #15C scalpel on stone cast. Trimmed/polished for patient comfort while maintaining reference points. Serves as fixed coronal landmark for UNC-15 probe insertion during CAL/PPD measurements at baseline, weeks 4, 8, 12. Ensures measurement reproducibility (±0.5 mm) across examiners/timepoints. Autoclaved between visits.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Attachment Level (CAL)Time frame: Baseline, Weeks 4, 8, 12
- Change in Probing Pocket Depth (PPD)Time frame: Baseline, Weeks 4, 8, 12
- Bleeding on Probing (BOP)Time frame: Baseline, Weeks 4, 8, 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
faculty of dentistry Assiut University
Asyut, Egypt
faculty of dentistry Assiut University
Asyut, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.